In the latest attempt to bring drug spending under control, the U.K.’s National Health Service reached what it calls a “first-of-its-kind” agreement with three drug makers to provide hepatitis C medicines at “best prices” in hopes of eradicating the disease.
Five-year agreements were reached with Gilead Sciences (GILD), AbbVie (ABBV), and Merck (MRK), which will also work with local health services and voluntary groups to find patients —including homeless people and those with mental health problems — test for infection, and provide treatment. About 113,000 people in England are estimated to have the chronic liver disease.
About the Author Reprints
